Clinical trial
Lipitor as a Treatment for Alzheimer's Disease
NCT00024531 · Institute for the Study of Aging (ISOA), Other · Completed
Key facts
| NCT number | NCT00024531 |
|---|---|
| Title | Lipitor as a Treatment for Alzheimer's Disease |
| Official title | Effect of the HMG-CoA Reductase Inhibitor Atorvastatin Calcium, Lipitor, in the Treatment of Alzheimer's Disease |
| Lead sponsor | Institute for the Study of Aging (ISOA), Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | Atorvastatin calcium |
| Enrollment | 98 |
| Start date | Oct 1, 2000 |
| Completion | Aug 1, 2004 |
| First posted | Sep 20, 2001 |
| Last update posted | Nov 9, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: